Sonnet Biotherapeutics Holdings Inc.

Sonnet Biotherapeutics Holdings Inc. is a biotechnology company focused on developing targeted biologic drugs to treat a variety of cancer indications. Founded with a mission to innovate cancer treatment, the company employs its proprietary platform technology, FHAB (Fully Human Albumin Binding), to enhance the efficacy and tolerability of immune therapeutics. This innovative approach is designed to improve drug delivery, extend half-life, and increase therapeutic potency while minimizing adverse effects. Sonnet Biotherapeutics actively engages in the research and development of a diverse pipeline of therapeutic candidates aimed at addressing unmet medical needs in oncology. Its efforts hold significant promise in impacting the medical and pharmaceutical sectors by potentially introducing breakthrough treatments for challenging oncological conditions. In the dynamic realm of biotechnology, Sonnet Biotherapeutics serves a crucial role in advancing cancer therapeutics, aligning with the growing demand for more effective, targeted treatment solutions.